Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy

Molecular Pharmaceutics

Volumn 11, Issue 3, 2014, Pages 1075-1080

  Bremer, Paul T ^a   Schlosburg, Joel E ^a   Lively, Jenny M ^a   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

adjuvant; analgesia; antibody; CpG ODN; dose response; heroin; route of administration; vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DIAMORPHINE; DRUGS USED IN THE TREATMENT OF ADDICTION; HEROIN VACCINE; MORPHINE; UNCLASSIFIED DRUG; VACCINE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; ANALGESIC AGENT; ANTIBODY; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEROIN DEPENDENCE; HOT PLATE TEST; IC 50; MALE; MOUSE; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; TAIL IMMERSION TEST; VACCINATION; AGONISTS; ANIMAL; BLOOD; CHEMISTRY; DRUG ADMINISTRATION ROUTE; IMMUNIZATION; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VETERINARY;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANALGESICS; ANIMALS; ANTIBODIES; DRUG ADMINISTRATION ROUTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEROIN; HEROIN DEPENDENCE; IMMUNIZATION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; OLIGODEOXYRIBONUCLEOTIDES; RATS; TOLL-LIKE RECEPTOR 9; VACCINES, CONJUGATE;

EID: 84901741086     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400631w     Document Type: Article

References (33)

1. Mark, T. L.; Woody, G. E.; Juday, T.; Kleber, H. D. The economic costs of heroin addiction in the United States Drug Alcohol Depend. 2001, 61 (2) 195-206
2. Lin, S. H.; Chen, K. C.; Lee, S. Y.; Hsiao, C. Y.; Lee, I. H.; Yeh, T. L.; Chen, P. S.; Lu, R. B.; Yang, Y. K. The economic cost of heroin dependency and quality of life among heroin users in Taiwan Psychiatry Res. 2013, 209 (3) 512-7
3. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings; NSDUH Series H-41, HHS Publication No. (SMA) 11-4658; Substance Abuse and Mental Health Services Administration: Rockville, MD, 2011.
4. Centers for Disease Control and Prevention. WONDER (database); US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2012. Available at http://wonder.cdc.gov.
5. Bonese, K. F.; Wainer, B. H.; Fitch, F. W.; Rothberg, R. M.; Schuster, C. R. Changes in heroin self-administration by a rhesus monkey after morphine immunisation Nature 1974, 252 (5485) 708-10
6. Anton, B.; Leff, P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents Vaccine 2006, 24 (16) 3232-40
7. Pravetoni, M.; Raleigh, M. D.; Le Naour, M.; Tucker, A. M.; Harmon, T. M.; Jones, J. M.; Birnbaum, A. K.; Portoghese, P. S.; Pentel, P. R. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats Vaccine 2012, 30 (31) 4617-24
8. Stowe, G. N.; Vendruscolo, L. F.; Edwards, S.; Schlosburg, J. E.; Misra, K. K.; Schulteis, G.; Mayorov, A. V.; Zakhari, J. S.; Koob, G. F.; Janda, K. D. A vaccine strategy that induces protective immunity against heroin J. Med. Chem. 2011, 54 (14) 5195-204
9. Schlosburg, J. E.; Vendruscolo, L. F.; Bremer, P. T.; Lockner, J. W.; Wade, C. L.; Nunes, A. A.; Stowe, G. N.; Edwards, S.; Janda, K. D.; Koob, G. F. Dynamic vaccine blocks relapse to compulsive intake of heroin Proc. Natl. Acad. Sci. U.S.A. 2013, 110 (22) 9036-41
10. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; Akira, S. A Toll-like receptor recognizes bacterial DNA Nature 2000, 408 (6813) 740-5
11. Hartmann, G.; Krieg, A. M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells J. Immunol. 2000, 164 (2) 944-53
12. Weeratna, R. D.; McCluskie, M. J.; Xu, Y.; Davis, H. L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants Vaccine 2000, 18 (17) 1755-62
13. Brazolot Millan, C. L.; Weeratna, R.; Krieg, A. M.; Siegrist, C. A.; Davis, H. L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (26) 15553-8
14. Weeratna, R.; Comanita, L.; Davis, H. L. CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB//c mice Immunol. Cell Biol. 2003, 81 (1) 59-62
15. Zakhartchouk, A. N.; Sharon, C.; Satkunarajah, M.; Auperin, T.; Viswanathan, S.; Mutwiri, G.; Petric, M.; See, R. H.; Brunham, R. C.; Finlay, B. B.; Cameron, C.; Kelvin, D. J.; Cochrane, A.; Rini, J. M.; Babiuk, L. A. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine Vaccine 2007, 25 (1) 136-43
16. Cooper, C. L.; Davis, H. L.; Morris, M. L.; Efler, S. M.; Adhami, M. A.; Krieg, A. M.; Cameron, D. W.; Heathcote, J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study J. Clin. Immunol. 2004, 24 (6) 693-701
17. Mullen, G. E.; Ellis, R. D.; Miura, K.; Malkin, E.; Nolan, C.; Hay, M.; Fay, M. P.; Saul, A.; Zhu, D.; Rausch, K.; Moretz, S.; Zhou, H.; Long, C. A.; Miller, L. H.; Treanor, J. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria PloS One 2008, 3 (8) e2940
18. Sogaard, O. S.; Lohse, N.; Harboe, Z. B.; Offersen, R.; Bukh, A. R.; Davis, H. L.; Schonheyder, H. C.; Ostergaard, L. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial Clin. Infect. Dis. 2010, 51 (1) 42-50
19. Valmori, D.; Souleimanian, N. E.; Tosello, V.; Bhardwaj, N.; Adams, S.; O'Neill, D.; Pavlick, A.; Escalon, J. B.; Cruz, C. M.; Angiulli, A.; Angiulli, F.; Mears, G.; Vogel, S. M.; Pan, L.; Jungbluth, A. A.; Hoffmann, E. W.; Venhaus, R.; Ritter, G.; Old, L. J.; Ayyoub, M. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (21) 8947-52
20. Brody, J. D.; Ai, W. Z.; Czerwinski, D. K.; Torchia, J. A.; Levy, M.; Advani, R. H.; Kim, Y. H.; Hoppe, R. T.; Knox, S. J.; Shin, L. K.; Wapnir, I.; Tibshirani, R. J.; Levy, R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study J. Clin. Oncol. 2010, 28 (28) 4324-32
21. Bremer, P. T.; Janda, K. D. Investigating the Effects of a Hydrolytically Stable Hapten and a Th1 Adjuvant on Heroin Vaccine Performance J. Med. Chem. 2012, 55 (23) 10776-80
22. Schlosburg, J. E.; Radanova, L.; Di Marzo, V.; Imming, P.; Lichtman, A. H. Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice Behav. Pharmacol. 2012, 23 (7) 722-6
23. Chen, X.; Pravetoni, M.; Bhayana, B.; Pentel, P. R.; Wu, M. X. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants Vaccine 2012, 31 (1) 159-64
24. Ajana, F.; Sana, C.; Caulin, E. [Are there differences in immunogenicity and safety of vaccines according to the injection method?] Med. Mal. Infect. 2008, 38 (12) 648-57
25. Eisenbarth, S. C.; Colegio, O. R.; O'Connor, W.; Sutterwala, F. S.; Flavell, R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants Nature 2008, 453 (7198) 1122-6
26. Tilney, N. L. Patterns of lymphatic drainage in the adult laboratory rat J. Anat. 1971, 109 (Part 3) 369-83
27. Noe, S. M.; Green, M. A.; HogenEsch, H.; Hem, S. L. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response Vaccine 2010, 28 (20) 3588-94
28. Bachmann, M. F.; Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 2010, 10 (11) 787-96
29. McCluskie, M. J.; Pryde, D. C.; Gervais, D. P.; Stead, D. R.; Zhang, N.; Benoit, M.; Robertson, K.; Kim, I. J.; Tharmanathan, T.; Merson, J. R.; Davis, H. L. Enhancing immunogenicity of a 3′aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates Int. Immunopharmacol. 2013, 16 (1) 50-6
30. Davis, H. L.; Weeratna, R.; Waldschmidt, T. J.; Tygrett, L.; Schorr, J.; Krieg, A. M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen J. Immunol. 1998, 160 (2) 870-6
31. Sora, I.; Takahashi, N.; Funada, M.; Ujike, H.; Revay, R. S.; Donovan, D. M.; Miner, L. L.; Uhl, G. R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (4) 1544-9
32. Moreno, A. Y.; Azar, M. R.; Warren, N. A.; Dickerson, T. J.; Koob, G. F.; Janda, K. D. A critical evaluation of a nicotine vaccine within a self-administration behavioral model Mol. Pharmaceutics 2010, 7 (2) 431-41
33. Duryee, M. J.; Bevins, R. A.; Reichel, C. M.; Murray, J. E.; Dong, Y.; Thiele, G. M.; Sanderson, S. D. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines Vaccine 2009, 27 (22) 2981-8